ବ୍ରୋଲୁସିଜୁମାବ

ବ୍ରୋଲୁସିଜୁମାବ
Monoclonal antibody
Type	Single-chain variable fragment
Source	Humanized
Target	Vascular endothelial growth factor A (VEGFA)
Clinical data
Trade names	Beovu, Vsiqq
Synonyms	Brolucizumab-dbll, ESBA1008, RTH258, DLX1008
AHFS/Drugs.com	monograph
MedlinePlus	a620001
data	US DailyMed: Brolucizumab;
Pregnancy; category	AU: D ; US: N (Not classified yet) ; ;
Routes of; administration	Intravitreal
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Chemical and physical data
Formula	C1164H1768N310O372S7
Molar mass	୨୬,୨୮୧.୧୭ g·mol−1

ବ୍ରୋଲୁସିଜୁମାବ, ବିକ୍ରୟ ନାମ ବେଭୋ ଏବଂ ଭିସିକ୍, ଏକ ଔଷଧ ଯାହା ବୟସ-ସମ୍ପର୍କୀୟ ମାକୁଲାର ଡିକେନେରେସନ (AMD) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୫] ଏହା ଆଖିରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେସ୍ୱଳ୍ପ ଭିଜୁଆଲ୍ ଆକ୍ୟୁଟି, ମୋତିଆବିନ୍ଦୁ, କଞ୍ଜୁକ୍ଟାଇଭାଲ୍ ରକ୍ତସ୍ରାବ ଏବଂ ଫ୍ଲୋଟର ହୋଇପାରେ । ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅନ୍ଧତ୍ୱ, ଆଖି ଭିତରେ ସଂକ୍ରମଣ, ରେଟିନାଲ୍ ଧମନୀ ଅବରୋଧ ଓ ନେତ୍ରପଟଳ ସ୍ଖଳନ ହୋଇପାରେ ।ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ଶିଶୁର କ୍ଷତି କରିପାରେ । ^[୬] ଏହା ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡିର ଏକ ଖଣ୍ଡ ଯାହା ଭାସ୍କୁଲାର ଏଣ୍ଡୋଥେଲିଆଲ୍ ଅଭିବୃଦ୍ଧି କାରକ ଏ ଭିଇଜିଏଫ-ଏ (A (VEGF-A)କୁ ସଂଲଗ୍ନ କରେ ଏବଂ ଅବରୋଧ କରେ । ଭିଇଜିଏଫ-ଏ ହେଉଛି ଏକ ପୁଷ୍ଟସାର ଯାହା ରକ୍ତନଳୀକୁ ବୃଦ୍ଧି କରାଏ ଏବଂ ତରଳ ପଦାର୍ଥ ଲିକ୍ କରିଥାଏ |

୨୦୧୯ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୨୦ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ବ୍ରୋଲୁସିଜୁମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ଏକ ମାତ୍ରାର ମୂଲ୍ୟ ପ୍ରାୟ ୧,୯୫୦ ଡଲାର ଅଟେ । ^[୭]

ଆଧାର

↑ "Brolucizumab (Beovu) Use During Pregnancy". Drugs.com. 24 October 2019. Retrieved 3 May 2020.
↑ "Beovu EPAR". European Medicines Agency (EMA). 10 December 2019. Archived from the original on 8 November 2020. Retrieved 3 May 2020. This article incorporates text from this source, which is in the public domain.
↑ "Beovu 120 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 9 March 2020. Archived from the original on 24 September 2020. Retrieved 3 May 2020.
↑ ^୪.୦ ^୪.୧ "Beovu- brolucizumab injection, solution". DailyMed. 13 January 2020. Archived from the original on 9 January 2021. Retrieved 3 May 2020.
↑ ^୫.୦ ^୫.୧ "Beovu- brolucizumab injection, solution". DailyMed. 13 January 2020. Archived from the original on 9 January 2021. Retrieved 3 May 2020.
↑ "Brolucizumab (Beovu) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 12 January 2022.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1235. ISBN 978-0857114105.

[Drugs.com_pregnancy-1] "Brolucizumab (Beovu) Use During Pregnancy". Drugs.com. 24 October 2019. Retrieved 3 May 2020.

[EPAR2022-2] "Beovu EPAR". European Medicines Agency (EMA). 10 December 2019. Archived from the original on 8 November 2020. Retrieved 3 May 2020. This article incorporates text from this source, which is in the public domain.

[3] "Beovu 120 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 9 March 2020. Archived from the original on 24 September 2020. Retrieved 3 May 2020.

[autogen1-4] ୪.୦ ^୪.୧ "Beovu- brolucizumab injection, solution". DailyMed. 13 January 2020. Archived from the original on 9 January 2021. Retrieved 3 May 2020.

[PI2022-5] ୫.୦ ^୫.୧ "Beovu- brolucizumab injection, solution". DailyMed. 13 January 2020. Archived from the original on 9 January 2021. Retrieved 3 May 2020.

[6] "Brolucizumab (Beovu) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 12 January 2022.

[BNF81-7] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1235. ISBN 978-0857114105.

[୫]

[୪]

[୧]

[୩]

[୨]

[୬]

[୭]